Form 8-K - Current report:
SEC Accession No. 0001193125-25-047244
Filing Date
2025-03-05
Accepted
2025-03-05 16:35:26
Documents
13
Period of Report
2025-03-04
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d940314d8k.htm   iXBRL 8-K 23538
  Complete submission text file 0001193125-25-047244.txt   148422

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA inab-20250304.xsd EX-101.SCH 2834
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE inab-20250304_lab.xml EX-101.LAB 18736
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE inab-20250304_pre.xml EX-101.PRE 11696
15 EXTRACTED XBRL INSTANCE DOCUMENT d940314d8k_htm.xml XML 3752
Mailing Address EMPIRE STATE BUILDING 350 5TH AVENUE, SUITE 5330 NEW YORK NY 10118
Business Address EMPIRE STATE BUILDING 350 5TH AVENUE, SUITE 5330 NEW YORK NY 10118 (646) 600-6438
IN8BIO, INC. (Filer) CIK: 0001740279 (see all company filings)

EIN.: 825462585 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39692 | Film No.: 25711782
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)